NICE - Endorsed Technology Appraisals 2010/2011

Technology Appraisals

Fully Endorsed

National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA171 - Lenalidomide for Multiple Myeloma - HSC (SQSD) (NICE) 06/2010

National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA176 - Cetuximab for the First-line Treatment of Metastatic Colorectal Cancer - HSC (SQSD) (NICE) 14/2010

• This guidance has been updated and replaced by TA439 - Cetuximab and panitumumab for previously untreated metastatic colorectal cancer, which was endorsed by the DoH in April 2017.

National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA177 - Alitretinoin for the Treatment of Severe Chronic Hand Eczema - HSC (SQSD) (NICE) 15/2010

National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA178 - Bevacizumab (first-line), Sorafenib (first and second-line), Sunitinib (second-line) and Temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma - HSC (SQSD) (NICE) 16/2010

National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA179 - Sunitinib for the Treatment of Gastrointestinal Stromal Tumours - HSC (SQSD) (NICE) 17/2010

National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA180 - Ustekinumab for the Treatment of Adults with Moderate to Severe Psoriasis - HSC (SQSD) (NICE) 18/2010

National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA181 - Pemetrexed for the First-Line Treatment of Non-Small-Cell Lung Cancer - HSC (SQSD) (NICE) 19/2010

National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA182 - Prasugrel for the treatment of acute coronary syndromes with percutaneous coronary intervention - HSC (SQSD) (NICE) 10/2010

National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA183 - Topotecan for the treatment of recurrent carcinoma of the cervix - HSC (SQSD) (NICE) 11/2010

National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA184 - Topotecan for the treatment of relapsed small-cell lung cancer - HSC (SQSD) (NICE) 12/2010

National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA189 - Sorafenib for the Treatment of Advanced Hepatocellular Carcinoma - HSC (SQSD) (NICE) 05/2011

• This guidance has been updated and replaced by TA474 - Sorafenib for treating advanced hepatocellular carcinoma, which was endorsed by the DoH in September 2017.

National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA196 - Imatinib for the Adjuvant Treatment of Gastrointestinal Stromal Tumours - HSC (SQSD) (NICE) 11/2011

National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA210 - Clopidogrel and Modified-Release Dipyridamole for the Prevention of Occular Vascular Events - HSC (SQSD) (NICE) 12/2011

National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA211 - Prucalopride for the Treatment of Chronic Constipation in Women - HSC (SQSD) (NICE) 06/2011